Janssen-Cilag International NV

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Johnson & Johnson seeks first EU approval of nipocalimab to

Janssen-Cilag submits MAA to EMA for nipocalimab, an FcRn blocker for gMG, based on Phase 3 Vivacity-MG3 study results showing sustained disease control in antibody-positive patients over 24 weeks.

Related Clinical Trials:

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

globenewswire.com

4 months ago

Prophylactic dexamethasone regimen reduces infusion-related

The 8 mg dexamethasone pre-medication regimen reduced infusion-related reaction (IRR) rates with intravenous amivantamab to 22.5%, a three-fold decrease from historical 67.4% rates.

Related Clinical Trials:

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Home Terms & Conditions Privacy Policy